Brokerages Set uniQure N.V. (NASDAQ:QURE) Price Target at $47.17

Shares of uniQure N.V. (NASDAQ:QURE) have been assigned an average recommendation of “Moderate Buy” from the seventeen brokerages that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and twelve have issued a buy rating on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $58.9167.

QURE has been the subject of several research reports. The Goldman Sachs Group upped their price objective on shares of uniQure from $14.00 to $46.00 and gave the company a “neutral” rating in a research note on Thursday, June 18th. Stifel Nicolaus set a $28.00 target price on shares of uniQure in a research note on Tuesday, May 5th. Mizuho upgraded uniQure from a “neutral” rating to an “outperform” rating and upped their price target for the company from $12.00 to $35.00 in a research report on Wednesday, March 11th. Royal Bank Of Canada increased their price target on uniQure from $35.00 to $65.00 and gave the company an “outperform” rating in a report on Thursday, June 18th. Finally, Leerink Partners lifted their price objective on uniQure from $36.00 to $70.00 and gave the stock an “outperform” rating in a research report on Thursday, June 18th.

uniQure News Summary

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: uniQure completed pricing on an upsized offering of 4,945,055 ordinary shares at $45.50 each, expected to raise about $225 million in gross proceeds. The added capital should strengthen the balance sheet and help fund its gene therapy pipeline. Article Title
• Neutral Sentiment: The company said the offering is expected to close around June 25, with underwriters also having a 30-day option to buy additional shares. This keeps financing flexibility high, but the near-term impact depends on completion and investor reception. Article Title
• Negative Sentiment: Investors appear worried about dilution because the company is issuing new shares rather than using debt. That pressure likely contributed to the stock’s weakness despite the capital raise. Article Title
• Negative Sentiment: Recent insider selling by the CEO and several directors may also weigh on sentiment, even though some trades were made under pre-arranged plans. Article Title

Insider Transactions at uniQure

In related news, CEO Matthew C. Kapusta sold 164,429 shares of the company’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $44.32, for a total value of $7,287,493.28. Following the transaction, the chief executive officer directly owned 558,810 shares in the company, valued at approximately $24,766,459.20. This represents a 22.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Madhavan Balachandran sold 11,685 shares of the company’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $45.06, for a total transaction of $526,526.10. Following the completion of the transaction, the director directly owned 43,254 shares in the company, valued at $1,949,025.24. The trade was a 21.27% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 324,134 shares of company stock valued at $12,778,769 in the last ninety days. 4.65% of the stock is currently owned by corporate insiders.

Institutional Trading of uniQure

A number of institutional investors and hedge funds have recently bought and sold shares of QURE. Woodline Partners LP boosted its stake in shares of uniQure by 25.0% in the first quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company’s stock valued at $1,864,000 after purchasing an additional 35,175 shares during the period. Legal & General Group Plc acquired a new stake in uniQure during the 2nd quarter worth approximately $497,000. Marshall Wace LLP raised its stake in shares of uniQure by 276.5% in the second quarter. Marshall Wace LLP now owns 222,979 shares of the biotechnology company’s stock valued at $3,108,000 after acquiring an additional 163,749 shares in the last quarter. California State Teachers Retirement System purchased a new position in uniQure in the second quarter valued at $540,000. Finally, Ameriprise Financial Inc. boosted its holdings in uniQure by 38.6% in the second quarter. Ameriprise Financial Inc. now owns 761,948 shares of the biotechnology company’s stock valued at $10,622,000 after purchasing an additional 212,218 shares during the period. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

uniQure Stock Down 0.4%

NASDAQ QURE opened at $48.85 on Thursday. The business has a fifty day moving average price of $26.59 and a 200 day moving average price of $22.65. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.40 and a current ratio of 10.40. The company has a market cap of $3.08 billion, a P/E ratio of -14.04 and a beta of 0.98. uniQure has a one year low of $8.73 and a one year high of $71.50.

uniQure (NASDAQ:QURE) last released its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.03. The business had revenue of $3.56 million during the quarter, compared to analyst estimates of $5.21 million. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. Research analysts anticipate that uniQure will post -3.64 EPS for the current fiscal year.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.